Friday, December 05, 2025 | 04:53 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

'It's nightmarish': Uphill task as Bharat Biotech gears for vaccine rollout

Bharat has already produced about 10 million doses of its Covaxin shot, ahead of an anticipated roll out by the middle of next year

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
premium

The lack of phase III trial data didn’t stop Bharat from applying for emergency use authorization this month.

Chris Kay | Bloomberg
The developer of India’s leading indigenous coronavirus vaccine is already producing millions of doses of its yet-to-be-approved candidate, but the thought of supplying enough shots for half the country’s nearly 1.4 billion people can seem daunting at times.

“It’s nightmarish,” said Suchitra Ella, joint managing director of Bharat Biotech International Ltd. “Sometimes I get goosebumps, sometimes I wake up early in the morning wondering where are we. What are we doing? How do we get there?”

Bharat has already produced about 10 million doses of its Covaxin shot, ahead of an anticipated roll out by the middle of next year.